Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shandong New Time Pharmaceutical Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to distinct examiners, but both are located within 1 distinct art unit. This indicates that the company's active pharmaceutical filings are being reviewed by different people within the same administrative group. The concentration in 1 art unit suggests a very specific technical focus for the company's current biotech applications.
KIFLE, BRUCK is the busiest examiner for the company, with 1 pending office action. Since there are 2 pending actions and multiple examiners, the workload is split evenly between the personnel. The fact that both examiners are within a single art unit means that the company's active matters are subject to the same supervisory policies. This provides a degree of administrative consistency despite the involvement of distinct examiners.
The 2 pending actions are distributed across examiners, and the busiest examiner, KIFLE, BRUCK, is responsible for 1 of these actions. The use of 1 art unit centralizes the technical oversight of the Biotechnology & Pharmaceuticals portfolio. This structure requires managing different examiner relationships within a single administrative environment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730071 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KIFLE, BRUCK | — |
| 18692470 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730071 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KIFLE, BRUCK | — | §112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18692470 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial